Core Viewpoint - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Bureau due to violations related to the management and use of raised funds, specifically regarding the purchase of non-principal guaranteed financial products without adequate risk disclosure [1][2]. Group 1: Regulatory Actions - The Guangdong Securities Regulatory Bureau issued a warning letter to Guangkang Biochemical and its executives, Cai Danqun and Chen Haixia, for failing to fulfill their responsibilities under the Information Disclosure Management Measures [2]. - The company was found to have used raised funds to purchase 179 financial products, of which 158 were non-principal guaranteed, without sufficient disclosure of the associated risks in their reports [1][2]. Group 2: Financial Details - Guangkang Biochemical was listed on the Shenzhen Stock Exchange's ChiNext on June 27, 2023, issuing 18.5 million shares at a price of 42.45 yuan per share, which currently trades below its initial offering price [2]. - The total amount raised by the company was 785.325 million yuan, with a net amount of 697.3657 million yuan after deducting issuance costs, which exceeded the initially planned amount by 6.1779 million yuan [2].

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

Core Viewpoint - Guangkang Biochemical (300804.SZ) received a warning letter from the Guangdong Securities Regulatory Bureau regarding the improper use of raised funds for cash management, specifically concerning the purchase of non-principal guaranteed financial products [1] Group 1: Regulatory Actions - The company was issued a warning letter (Decision No. [2025] 179) by the Guangdong Securities Regulatory Bureau [1] - The investigation covered the period from July 2023 to August 2025, during which the company used raised funds to purchase 179 financial products [1] Group 2: Financial Product Purchases - Out of the 179 financial products purchased, 158 were non-principal guaranteed products [1] - The breakdown of non-principal guaranteed product purchases was as follows: 14 in 2023, 68 in 2024, and 76 in 2025 [1] Group 3: Disclosure Issues - The company failed to adequately disclose the risks associated with purchasing non-principal guaranteed financial products in its annual reports [1] - Despite not incurring any principal losses, the company's actions did not comply with regulatory requirements outlined in the "Regulatory Guidelines for Listed Companies on the Management and Use of Raised Funds" [1]

Core Viewpoint - Guangkang Biotech (300804.SZ) received a warning letter from the Guangdong Securities Regulatory Bureau regarding the improper management of raised funds, specifically concerning the purchase of non-principal guaranteed financial products without adequate disclosure of associated risks [1] Group 1: Regulatory Actions - The company was issued a warning letter (Decision No. 〔2025〕179) by the Guangdong Securities Regulatory Bureau [1] - The investigation covered the period from July 2023 to August 2025, during which the company engaged in cash management using raised funds [1] Group 2: Fund Management Practices - The company executed 179 transactions to purchase financial products, of which 158 were non-principal guaranteed products [1] - The breakdown of non-principal guaranteed product purchases includes 14 in 2023, 68 in 2024, and 76 in 2025 [1] - The company failed to adequately disclose the risks of potential principal loss in its annual reports regarding the use of raised funds [1] Group 3: Compliance Violations - The company's actions were found to be non-compliant with the regulatory requirements outlined in the "Guidelines for the Supervision of Listed Companies on the Management and Use of Raised Funds" [1] - Violations included not fully disclosing the safety of principal when using raised funds for cash management [1]

广康生化公告，公司因在2023年7月至2025年8月期间，循环使用募集资金滚动购买179笔理财产品，其 中有158笔为非保本理财产品，且在相应年度《募集资金存放与使用专项报告》中未充分披露使用募集 资金进行现金管理的本金安全性问题，收到广东证监局出具的警示函。 ...

广东广康生化科技股份有限公司（以下简称"公司"）于近日收到中国证券监督 管理委员会广东监管局（以下简称"广东证监局"）出具的《关于对广东广康生化科 技股份有限公司、蔡丹群、陈海霞采取出具警示函措施的决定》（〔2025〕179 号） （以下简称"《警示函》"）。现将具体情况公告如下： 一、《警示函》的内容 "广东广康生化科技股份有限公司、蔡丹群、陈海霞： 根据《上市公司现场检查规则》(证监会公告〔2025〕5 号)等规定，我局近期 对广东广康生化科技股份有限公司（以下简称广康生化或公司）进行了现场检查， 发现公司存在以下问题： 证券代码：300804 证券简称：广康生化 公告编号：2026-001 广东广康生化科技股份有限公司 关于公司及相关人员收到广东证监局警示函的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 二款第一项的规定，违反了《上市公司信息披露管理办法》（证监会令第 182 号， 下同）第三条第一款的规定。 公司及相关人员收到《警示函》后，对函件中指出的问题高度重视，并将认真吸 取教训、深入反思，严格落实整改措施，切实加强对《上市公司信息披露管 ...

（文章来源：证券日报） 证券日报网讯 12月24日，广康生化发布公告称，公司第四届董事会第四次会议审议通过《关于使用自 有资金支付募投项目部分款项并以募集资金等额置换的议案》。 ...

每经AI快讯，广康生化（SZ 300804，收盘价：35.05元）12月24日晚间发布公告称，公司第四届第四次 董事会会议于2025年12月23日以通讯表决方式召开。会议审议了《关于使用自有资金支付募投项目部分 款项并以募集资金等额置换的议案》等文件。 2024年1至12月份，广康生化的营业收入构成为：农药占比99.84%，其他业务占比0.16%。 截至发稿，广康生化市值为26亿元。 每经头条（nbdtoutiao）——左手"欠款"右手"豪购"！杨陵江收购"国内酒庄第一股"，1919是否重启上 市？"吹太多牛都实现了，但千亿还没实现，我很着急" （记者 曾健辉） ...

证券代码：300804 证券简称：广康生化 公告编号：2025-061 广东广康生化科技股份有限公司 第四届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 广东广康生化科技股份有限公司（以下简称"公司"）第四届董事会第四次会议 于 2025 年 12 月 23 日以通讯表决方式召开。会议通知已于 2025 年 12 月 19 日通过邮 件和即时通讯工具的方式送达各位董事。本次应出席会议的董事 7 名，实际出席会议 的董事 7 名。本次会议由董事长蔡丹群先生召集并主持，公司全体高级管理人员列席 了会议，会议的召集、召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 和《广东广康生化科技股份有限公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过《关于使用自有资金支付募投项目部分款项并以募集资金等额置换 的议案》 经审议，同意公司全资子公司湖北晟康化工有限公司及其广州分公司在不影响募 投项目正常进行的前提下，根据实际情况先以自有资金支付募投项目相关款项，后续 定期统计自有资金垫付金额并完成募集资金等 ...

核查意见 华泰联合证券有限责任公司 关于广东广康生化科技股份有限公司 使用自有资金支付募投项目部分款项 并以募集资金等额置换的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为广东广康生化科技股份有限公司（以下简称"广康生化"或"公司"）首次公 开发行股票并在创业板上市持续督导阶段的保荐人，根据《证券发行上市保荐业 务管理办法》《上市公司募集资金监管规则》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》及《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等有关 规定，对广康生化本次拟使用自有资金支付募投项目部分款项并以募集资金等额 置换事项进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会 2023 年 5 月 9 日出具的《关于核准广东广康 生化科技股份有限公司首次公开发行股票注册的批复》（证监许可[2023]1008 号）， 公司获核准向社会公开发行不超过 1,850.00 万股新股，该批复自同意核准发行之 日起 12 个月内有效。截至 2023 年 6 月 20 日止，公 ...